Clinical Trial Update: Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the pharmacokinetic and pharmacodynamic interaction between the experimental agent BIA 3-202 and levodopa/benserazide in Parkinson's di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 3-202
• Levodopa/Benserazide (levodopa + benserazide)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson's Disease (PD) | Phase 1 | Status: COMPLETED